Table 1. Parameters used in the base case analysis for pneumococcal vaccination in Kenyan infants born in 2010 *BCV- Base case value.

Parameter	Base case	Reference	Statistical distribution	Source
IPD incidence (per 105 child-years)
Meningitis
0–11 months	48.3	Kilifi HDSS	Poisson (48.3)	Kilifi HDSS
12–23 months	22.4		Poisson (22.4)
24–59 months	5.0		Poisson (5)
Sepsis
0–11 months	27.4	Kilifi HDSS	Poisson (27.4)	Kilifi HDSS
12–23 months	27.2		Poisson (27.2)
24–59 months	13.4		Poisson (13.4)
Bacteraemic pneumonia
0–11 months	74.0	Kilifi HDSS	Poisson(74)	Kilifi HDSS
12–23 months	41.6		Poisson(41.6)
24–59 months	17.8		Poisson(17.8)
Non-bacteraemic pneumonia
0–11 months	972.9	Extrapolation fromCutts [4]	NA	Extrapolation from Cutts et al
12–23 months	592.9		NA
24–59 months	235.4		NA
Vaccination
PCV9 efficacy against serotype specific disease
Meningitis	92%	Cutts [4]	Beta(92,8)	Cutts et al
Sepsis	92%		Beta(92,8)
Bacteraemic pneumonia	77%		Beta(77,23)
Non-bacteraemic pneumonia	77%	Extrapolated fromCutts [4]	Beta(77,23)	Extrapolation from Cutts et al
Access to healthcare
Outpatient care	37%	Kallander [23]	Beta (16,28)	Kallander et al
Inpatient hospital care	40%		Beta(18,26)
Health outcomes
Major post discharge meningitis sequelae	25%	Edmond [27]	Beta (25,75)	Edmond et al
Case fatality with hospital care
IPD (sepsis, bacteraemic pneumonia)	28.2%	Berkley, [41] expert opinion	Beta (28,72)	Berkley et al, expert opinion
Non-bacteraemic pneumonia	5.7%	Berkley, [41] expert opinion	Beta (6,94)	Berkley et al, expert opinion
Case fatality without hospital care
Meningitis	97%	Expert opinion	Beta (97,3)	Expert opinion
Sepsis and bacteraemic pneumonia	50%		Beta (4,4)
Non-bacteraemic pneumonia	12%		Beta (12,88)
Inpatient treatment costs
Meningitis	$357.74	Ayieko [28]	Gamma (4,19)	Ayieko et al
Sepsis or pneumonia	$74.64		Gamma (1,314)
Outpatient treatment cost
Childhood fever	$2.74	Larson [29]	NA	Larson et al
Discounting
Costs = 0%; effects = 0%	NA	Assumption	NA
Costs = 3%; effects = 3%	NA	Assumption	NA

NA- Not applicable.